Forte Biosciences Long-Term Debt 2011-2026 | FBRX

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Annual Long-Term Debt Forte Biosciences

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-	-	26.2 M	3.62 M	13.8 M	17 M	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
26.2 M	3.62 M	15.2 M

Quarterly Long-Term Debt Forte Biosciences

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.91 M	4.03 M	9.12 M	22.1 M	24.1 M	26.2 M	26.2 M	26.2 M	26.2 M	3.62 M	3.62 M	3.62 M	3.62 M	10.2 M	10.2 M	10.2 M	10.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
26.2 M	3.62 M	13.1 M

Long-Term Debt of other stocks in the Biotechnology industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	273 M	-	2.43 %	$ 254 M	Germany
Alector ALEC	9.32 M	$ 2.19	-9.77 %	$ 226 M	USA
Acer Therapeutics ACER	146 K	-	2.71 %	$ 14 M	USA
I-Mab IMAB	68.2 M	-	-	$ 866 M	China
Cabaletta Bio CABA	1.46 M	$ 3.34	0.45 %	$ 3.9 M	USA
Alexion Pharmaceuticals, Inc. ALXN	2.42 B	-	-	$ 40.3 B	USA
AgeX Therapeutics AGE	13.2 M	-	-10.17 %	$ 12.2 K	USA
Biophytis SA BPTS	1.83 M	-	-13.47 %	$ 169 M	France
Aeglea BioTherapeutics AGLE	4 M	-	-	$ 1.01 B	USA
Codexis CDXS	28.9 M	$ 1.02	1.49 %	$ 74.9 M	USA
AbCellera Biologics ABCL	137 M	$ 3.74	3.6 %	$ 1.12 B	Canada
Applied Genetic Technologies Corporation AGTC	9.12 M	-	-	$ 26.5 M	USA
Cerus Corporation CERS	11.7 M	$ 2.6	1.37 %	$ 480 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	278 K	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	4.76 M	-	-18.52 %	$ 27.3 M	Britain
Cellectis S.A. CLLS	28.8 M	$ 3.87	-0.39 %	$ 116 M	France
ARCA biopharma ABIO	755 K	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	167 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	410 K	-	4.01 %	$ 150 M	Canada
Adverum Biotechnologies ADVM	86 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	175 M	-	-	-	Russia
AIkido Pharma AIKI	2.63 M	-	1.93 %	$ 17.4 M	USA
Collegium Pharmaceutical COLL	4.13 M	$ 41.75	0.19 %	$ 1.32 B	USA
Akero Therapeutics AKRO	529 K	-	-	$ 3.67 B	USA
Akouos AKUS	28.3 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	9.62 M	-	-0.23 %	$ 916 M	USA
Corcept Therapeutics Incorporated CORT	5.02 M	$ 36.14	1.23 %	$ 3.75 B	USA
Allena Pharmaceuticals ALNA	210 K	-	3.16 %	$ 1.9 M	USA
Amarin Corporation plc AMRN	8.74 M	$ 13.98	1.27 %	$ 5.7 B	Irlanda
Aileron Therapeutics ALRN	69 K	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	16.6 M	-	4.14 %	$ 49.1 M	USA
Catalyst Pharmaceuticals CPRX	2.35 M	$ 23.77	2.99 %	$ 2.91 B	USA
Alpine Immune Sciences ALPN	3.38 M	-	-	$ 2.17 B	USA
Corbus Pharmaceuticals Holdings CRBP	16 M	$ 8.41	-1.87 %	$ 36.4 M	USA
Cardiff Oncology CRDF	102 K	$ 1.94	0.01 %	$ 130 M	USA
Curis CRIS	1.62 M	$ 1.1	-3.51 %	$ 6.94 M	USA
Aeterna Zentaris AEZS	31 K	-	5.93 %	$ 314 M	Canada
CorMedix CRMD	517 K	$ 7.16	0.42 %	$ 364 M	USA
Ampio Pharmaceuticals AMPE	274 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	49 K	-	-	$ 10.1 M	USA
Champions Oncology CSBR	85 K	$ 6.14	3.89 %	$ 83.9 M	USA
Aravive ARAV	1.88 M	-	-13.39 %	$ 1.45 M	USA
Aptose Biosciences APTO	193 K	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	22.1 M	-	-39.0 %	$ 4.57 M	USA
Citius Pharmaceuticals CTXR	21.3 K	$ 0.72	-2.34 %	$ 4.84 M	USA
Athira Pharma ATHA	803 K	-	-	$ 269 M	USA
Aridis Pharmaceuticals ARDS	1.29 M	-	17.91 %	$ 11.1 M	USA
Altimmune ALT	1.4 M	$ 4.21	-2.32 %	$ 299 M	USA
CEL-SCI Corporation CVM	7.96 M	$ 3.88	-8.92 %	$ 247 M	USA